Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non–small-cell lung cancer using a decision …
NA Pennell, A Mutebi, ZY Zhou, ML Ricculli… - JCO Precision …, 2019 - ascopubs.org
PURPOSE The aim of the current study was to assess the economic impact of using next-
generation sequencing (NGS) versus single-gene testing strategies among patients with …
generation sequencing (NGS) versus single-gene testing strategies among patients with …
Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with …
J Vanderpoel, AL Stevens, B Emond… - Journal of Medical …, 2022 - Taylor & Francis
Background To assess the total cost of testing associated with next-generation sequencing
(NGS) versus polymerase chain reaction (PCR) testing strategies among patients with …
(NGS) versus polymerase chain reaction (PCR) testing strategies among patients with …
[HTML][HTML] Diagnostic value and cost-effectiveness of next-generation sequencing–based testing for treatment of patients with advanced/metastatic non-squamous non …
D Zou, W Ye, LM Hess, NR Bhandari, A Ale-Ali… - The Journal of Molecular …, 2022 - Elsevier
The study evaluated the diagnostic value and cost-effectiveness of next-generation
sequencing (NGS)–based testing versus various combinations of single-gene tests (SGTs) …
sequencing (NGS)–based testing versus various combinations of single-gene tests (SGTs) …
Cost effectiveness of multigene panel sequencing for patients with advanced non–small-cell lung cancer
L Steuten, B Goulart, NJ Meropol… - JCO Clinical Cancer …, 2019 - ascopubs.org
PURPOSE Compared with single-marker genetic testing (SMGT), multigene panel
sequencing (MGPS) has the potential to identify more patients with cancer who could benefit …
sequencing (MGPS) has the potential to identify more patients with cancer who could benefit …
Comprehensive genomic profiling facilitates implementation of the national comprehensive cancer network guidelines for lung cancer biomarker testing and identifies …
JH Suh, A Johnson, L Albacker, K Wang… - The …, 2016 - academic.oup.com
Abstract Background. The National Comprehensive Cancer Network (NCCN) guidelines for
patients with metastatic non-small cell lung cancer (NSCLC) recommend testing for EGFR …
patients with metastatic non-small cell lung cancer (NSCLC) recommend testing for EGFR …
Association between availability of molecular genotyping results and overall survival in patients with advanced nonsquamous non–small-cell lung cancer
C Aggarwal, ME Marmarelis, WT Hwang… - JCO precision …, 2023 - ascopubs.org
PURPOSE Current guidelines recommend molecular genotyping for patients newly
diagnosed with metastatic nonsquamous (mNSq) non–small-cell lung cancer (NSCLC). The …
diagnosed with metastatic nonsquamous (mNSq) non–small-cell lung cancer (NSCLC). The …
Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non–small cell lung cancer
C Aggarwal, JC Thompson, TA Black, SI Katz… - JAMA …, 2019 - jamanetwork.com
Importance The clinical implications of adding plasma-based circulating tumor DNA next-
generation sequencing (NGS) to tissue NGS for targetable mutation detection in non–small …
generation sequencing (NGS) to tissue NGS for targetable mutation detection in non–small …
Practice-level variation in molecular testing and use of targeted therapy for patients with non–small cell lung cancer and colorectal cancer
Importance All patients with newly diagnosed non–small cell lung cancer (NSCLC) and
colorectal cancer (CRC) should receive molecular testing to identify those who can benefit …
colorectal cancer (CRC) should receive molecular testing to identify those who can benefit …
Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and …
AC Tan, GGY Lai, G San Tan, SY Poon, B Doble… - Lung Cancer, 2020 - Elsevier
Objectives There is an expanding list of therapeutically relevant biomarkers for non-small
cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition …
cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition …
[HTML][HTML] Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network
NJ Robert, JL Espirito, L Chen, E Nwokeji, M Karhade… - Lung Cancer, 2022 - Elsevier
Abstract Objectives The MYLUNG (Molecularly Informed Lung Cancer Treatment in a
Community Cancer Network) consortium pragmatic study assessed real-world biomarker …
Community Cancer Network) consortium pragmatic study assessed real-world biomarker …